Navigation Links
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
Date:8/5/2009

SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease. The funding will enable Ceregene to collect and analyze more extensive data for up to 48 months from patients with advanced Parkinson's disease who were enrolled in the double-blind, controlled trial which ended in November 2008.

As was previously announced, the Phase 2 trial of CERE-120 involving 52 patients, failed to demonstrate a difference in the primary endpoint between patients in the CERE-120 versus control group. It was subsequently announced, however, that CERE-120 suggested improvement on several secondary endpoints at 12 months, and at 18 months, a statistically significant treatment effect on the primary endpoint emerged, while several additional secondary endpoints also showed improvement. In contrast, on no measure did sham patients perform better than CERE-120 patients, at either 12 or 18 months. Based on those findings, and insight gained from analyses of post-mortem brain tissue from two CERE-120 treated patients, the company has revised the dosing regimen and expects to initiate a new trial of CERE-120 in the near future.

"We are pleased to be able to gather unique, long-term data from both CERE-120 treated and control patients and thus gain more information about the potential long-term effects of CERE-120 on Parkinson's disease," stated Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer. "We very much appreciate the support the MJFF has provided to enable us to expand the testing of these patients and further enrich our data base. Our conviction about CERE-120's potential to treat Parkinson's disease remains strong. We learned a significant amount from the initial Phase 2 trial wh
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
2. Ceregene Announces Two Key Additions to Leadership Team
3. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
6. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
7. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
8. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
9. SyntheMed Receives US Patent on Novel Polymer Technology
10. Sunesis Receives Approval for Listing on The NASDAQ Capital Market
11. Anesiva Receives NASDAQ Delisting Staff Determination Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Niceware International , a Milwaukee developer of bar ... seen identification software used to track parts in the ... matter of time before healthcare facilities came calling for ... 2002, has produced NiceLabel software for the automatic identification ...
... since the debut of MedTech Futures and it has been ... share ideas with through this forum. As this column enters ... briefly summarize some of the perspectives over the past year ... - namely personalized medicine. , , Medical technology and pharmaceuticals ...
... the state Division of Enterprise Technology is ... recently released audit of state information technology projects. , ... said he concurs with all the recommendations contained in ... executive-level agencies report by Oct. 1 of this year ...
Cached Biology Technology:Software company enters health space with RFID solutions on hold 2Software company enters health space with RFID solutions on hold 3Personalized medicine and technology convergence 2Personalized medicine and technology convergence 3Personalized medicine and technology convergence 4Personalized medicine and technology convergence 5Personalized medicine and technology convergence 6Personalized medicine and technology convergence 7Personalized medicine and technology convergence 8State technology chief endorses IT audit recommendations 2State technology chief endorses IT audit recommendations 3
(Date:4/23/2014)... 2014) A team of researchers in ... into the brains of nonhuman primates and assessed ... months found that the hNSCs had differentiated into ... tumors. , The study will be published in ... but is currently freely available on-line as an ...
(Date:4/23/2014)... the energy landscape in the U.S., but in ... the energy industry, residents and agricultural interests over ... degraded water quality is a potential risk unless ... in the ACS journal Environmental Science & ... point out that a major criticism of extracting ...
(Date:4/23/2014)... most comprehensive study to date of the family ... more effective vaccine strategies and reveals surprising findings ... results could alter public health strategies to control ... each year. , Genomic analysis of 343 strains ... around the world collected over the last 100 ...
Breaking Biology News(10 mins):Study finds long-term survival of human neural stem cells transplanted into primate brain 2How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2
... non-human primates, over 100 billion nerve cells build up ... an attempt is made to perform gene therapy for ... specify a responsible neural circuit out of many complicated ... a target gene into this particular circuit selectively. The ...
... has been named founding director of the George Washington ... further strengthen GW,s role as a leader in science ... As director, Dr. Crandall will define the scientific vision ... and implementation of research plans and organizational structures, with ...
... has not changed since the 2010-11 pilot run of the ... University of Arizona-led binational team of researchers. The 15,000-acre ... home to several endangered species and is a major stopover ... It lies within Mexico,s Biosphere Reserve for the Upper Gulf ...
Cached Biology News:Transgenic technique to 'eliminate' a specific neural circuit of the brain in primates 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 2Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 3Cinega de Santa Clara unchanged after pilot run of Yuma Desalting Plant 4
... assay kit designed to detect poly(ADP-ribose) polymerase ... an enzyme implicated in DNA damage and ... by caspase-3. Cleavage of PARP from the ... a hallmark of apoptosis. Each kit is ...
... comes with a shutter (controlled via a TTL ... The DH-2000 Deuterium Tungsten Halogen Light ... tungsten halogen light sources in a single optical ... stable output from 215-200 nm. In addition, deep-UV ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... Nematode microRNA Microarray contains all known ...
Biology Products: